What Is Metopimazine? Uses, Dosage, and Side Effects

Metopimazine is a dopamine D2 receptor antagonist used to prevent and treat nausea and vomiting. Marketed under the brand name Vogalène, it has been prescribed in France for over four decades, though it remains relatively unknown in many other countries.¹ What sets it apart from older anti-nausea drugs in the same class is that it works mostly outside the brain, which translates into fewer neurological side effects than many people associate with this category of medication.

How Metopimazine Works

Nausea and vomiting are coordinated by a region of the brainstem that sits just outside the blood-brain barrier, making it accessible to chemicals circulating in the blood. Dopamine is one of the signaling molecules that triggers this area. Metopimazine blocks dopamine D2 receptors there, interrupting the signal that tells your body to vomit. It also has some affinity for histamine H1 receptors and alpha-1 adrenergic receptors, but the anti-nausea effect is thought to come primarily from the dopamine blockade.²

One detail that matters clinically: metopimazine has no meaningful affinity for serotonin 5-HT3 receptors.² This is relevant because the most widely used anti-nausea drugs for chemotherapy, like ondansetron, work specifically by blocking 5-HT3 receptors. Since metopimazine and ondansetron target completely different receptor systems, they can be combined without overlapping or competing. That complementary mechanism is a major reason metopimazine has attracted research interest as an add-on therapy rather than a standalone treatment.

What Metopimazine Is Used For

The longest-established use is for chemotherapy-induced nausea and vomiting, one of the most dreaded side effects of cancer treatment. Chemotherapy can trigger both acute nausea (within the first 24 hours of a treatment cycle) and delayed nausea (which sets in on days two through five and is notoriously harder to control). Metopimazine has been studied for both phases.

In a trial published in the New England Journal of Medicine, the combination of ondansetron plus metopimazine significantly reduced both acute and delayed nausea and vomiting compared with ondansetron alone in patients receiving moderately emetogenic chemotherapy.³ A separate study compared metopimazine plus a steroid (methylprednisolone) against ondansetron plus the same steroid for delayed nausea specifically, and found the metopimazine combination prevented delayed vomiting in about 74% of patients compared with roughly 58% in the ondansetron group.⁴ That advantage for delayed symptoms is notable because delayed nausea remains a weak spot in existing anti-nausea regimens.

Beyond chemotherapy, metopimazine has been prescribed in France for general nausea and vomiting from various causes, including post-surgical nausea, motion sickness, and gastroenteritis. In everyday French pharmacy practice, Vogalène is something of a household name for garden-variety stomach upset, filling a role similar to what metoclopramide or domperidone fill in other countries.

The Gastroparesis Investigation

More recently, metopimazine has been investigated under the designation NG101 (metopimazine mesylate) for gastroparesis, a chronic condition in which the stomach empties too slowly, causing persistent nausea, bloating, and early fullness. Gastroparesis is a frustrating condition to treat because the FDA-approved options are very limited and often come with significant side effects.

A phase 2 randomized, placebo-controlled trial enrolled 161 participants with either diabetic or idiopathic gastroparesis. The headline nausea severity scores improved in all treatment groups, but these improvements did not reach statistical significance compared with placebo. There was, however, a statistically significant improvement in how patients rated their overall nausea experience during weeks one through twelve compared with placebo.⁵ That mixed result is worth understanding: the drug did not beat placebo on the primary nausea scale, but patients themselves reported feeling better. The disconnect may reflect the difficulty of measuring a subjective symptom like nausea with a standardized scoring instrument, or it may indicate a real but modest benefit. It leaves the gastroparesis application in an uncertain but potentially promising position, and further development continues.

An interesting pharmacological wrinkle applies here. While some dopamine-blocking antiemetics speed up gastric emptying (metoclopramide and domperidone are both prokinetic, meaning they help the stomach push food along), metopimazine actually delays gastric emptying.⁶ That sounds counterintuitive for a drug being tested in a slow-stomach condition. The rationale is that nausea in gastroparesis is not always tightly linked to how fast the stomach empties. Many patients with modest emptying delays have terrible nausea, while some with very slow stomachs report relatively little. Targeting the nausea signal directly, rather than trying to speed up motility, is a different therapeutic strategy.

Dosage

In France, the standard adult oral dose of metopimazine is 15 to 30 mg per day, typically divided into two or three doses. It is available in tablet, capsule, and oral liquid formulations. A suppository form also exists for situations where oral dosing is impractical, such as when a patient is actively vomiting.

For children, dosing is weight-based. A pharmacokinetic study in children given a single oral dose of about 0.33 mg per kilogram of body weight found that the drug was absorbed quickly, reaching peak blood levels within about an hour, with a half-life of roughly two hours. The study confirmed that children under 15 kg could be given 0.33 mg/kg up to three times per day.⁷ The short half-life means the drug does not accumulate significantly between doses, but it also means the anti-nausea effect fades relatively fast, which is why multiple daily doses are typically needed.

One pharmacokinetic detail that shapes metopimazine’s clinical profile: once you swallow the drug, your liver quickly converts it into a metabolite called metopimazine acid. Blood levels of this metabolite are substantially higher than levels of the parent drug and remain elevated for longer.⁷ In practical terms, it is the metabolite rather than the original compound that does most of the work in your body after an oral dose. This metabolite is also the form that has the hardest time crossing into the brain, which helps explain the favorable side-effect profile.

Side Effects and Safety

The side-effect conversation around metopimazine tends to focus on what it does not cause, because the drug class it belongs to (dopamine-blocking antiemetics) has a reputation for troublesome neurological effects. Drugs like metoclopramide can cause involuntary muscle movements, restlessness, and sometimes a condition called tardive dyskinesia with long-term use. These are known as extrapyramidal side effects, and they happen because the drug blocks dopamine receptors in the brain’s movement-control centers.

Metopimazine carries a low risk of these effects.⁶ The reason traces directly to poor brain penetration. A study using a laboratory model of the blood-brain barrier compared metopimazine’s ability to cross into the brain against domperidone, metoclopramide, and chlorpromazine. Metopimazine showed the lowest brain penetration of any compound tested, and its active metabolite, metopimazine acid, penetrated even less.⁸ Since the metabolite is the form that dominates in your blood after oral dosing, the net effect is a drug that blocks dopamine receptors where you want it to (at the vomiting trigger zone, which sits outside the blood-brain barrier) while largely sparing the brain’s internal circuitry.

That said, metopimazine is not side-effect-free. Like other dopamine-blocking antiemetics, it can potentially cause sedation and a drop in blood pressure when standing up (orthostatic hypotension).⁶ Some patients also report drowsiness, dry mouth, or mild digestive symptoms. The possibility of a prolonged QTc interval on an electrocardiogram, a marker for a rare but dangerous heart rhythm abnormality, is a class-wide concern for dopamine-blocking drugs. Your prescriber may want to check an ECG if you have pre-existing heart conditions or are taking other medications known to affect heart rhythm.

In pediatric cancer patients, a pilot study combining ondansetron with metopimazine reported no adverse events attributed to metopimazine.⁹ That is a small study, so it cannot rule out rare events, but it adds to the broader picture of a drug with a relatively gentle safety profile.

Use During Pregnancy and Breastfeeding

Nausea in pregnancy is incredibly common, and women understandably want to know whether any anti-nausea medication is safe for their baby. Metopimazine has been used during pregnancy in France, but formal data on its safety in pregnant women are limited, as is typical for most older drugs. Decisions about anti-nausea treatment during pregnancy are usually made on a case-by-case basis, weighing the severity of symptoms against what is known about a given drug’s risk profile.

For breastfeeding, a review of inquiries to a medicines information service concluded that commonly used antiemetics do not appear to pose an unacceptable risk to breastfed children older than six months. The authors recommended that the choice of antiemetic should rely on the woman’s symptoms and perceived benefit, rather than being restricted by breastfeeding status alone.¹⁰ That said, metopimazine was not individually singled out with a robust dataset, so you should discuss the specifics with your prescriber if this situation applies to you.

How Metopimazine Compares to Other Antiemetics

If you are familiar with anti-nausea drugs, you might wonder where metopimazine fits relative to the medications more commonly prescribed outside France. The comparison depends on what you are comparing for.

Against metoclopramide, the most widely available dopamine-blocking antiemetic worldwide, metopimazine’s main advantage is its reduced potential for movement-related side effects. Metoclopramide crosses into the brain more readily, which is why regulators in many countries have placed limits on how long patients can use it. Metopimazine has not carried those same restrictions in France. Metoclopramide has the edge in terms of prokinetic activity, though. If the goal is to get the stomach emptying faster, as in some cases of gastroparesis, metoclopramide directly stimulates that process. Metopimazine does not.

Against domperidone, the comparison is closer. Both are peripherally acting dopamine blockers with lower brain penetration than metoclopramide. But lab data suggest metopimazine penetrates the brain even less than domperidone.⁸ Domperidone is prokinetic; metopimazine is not. Both share the class-wide concern about QTc prolongation, which led to domperidone being restricted in some markets and never approved in the United States.

Against 5-HT3 receptor antagonists like ondansetron, metopimazine is not a competitor but a potential partner. The two drugs block entirely different receptor systems, so they can work together without diminishing each other’s effect. The clinical trials showing benefit from adding metopimazine to ondansetron illustrate this complementary relationship.³ In modern chemotherapy anti-nausea regimens, which often already include a 5-HT3 blocker, a steroid, and sometimes an NK1 receptor antagonist, metopimazine’s distinct mechanism means it could fill a gap without stepping on the other drugs’ actions.

Availability and Regulatory Status

Metopimazine has been marketed in France for over four decades under the Vogalène brand.¹ It is also available in some other European and African markets. It has never been approved in the United States, the United Kingdom, Canada, or most of Asia, which is why it is unfamiliar to most English-speaking patients and clinicians.

The recent clinical development of metopimazine mesylate (NG101) for gastroparesis represents an effort to bring the drug to the U.S. market through the FDA approval process. Gastroparesis is classified as an area of unmet medical need, which may smooth the regulatory path if the clinical data support approval. Whether the drug eventually reaches American pharmacies depends on the outcome of ongoing and future trials.

For patients in countries where metopimazine is not available, the drug occasionally comes up in online discussions as something that travelers or expatriates encounter in French pharmacies. Importing prescription medications from abroad is generally regulated and restricted in most countries, so “picking some up while in Paris” is not a straightforward option even if you have heard good things about it.

How the Liver Processes Metopimazine

Most dopamine-blocking drugs are broken down by the cytochrome P450 enzyme system in the liver, which creates the potential for drug interactions with the many other medications processed by those same enzymes. Metopimazine follows a different path. Research has shown it is primarily broken down by a liver amidase rather than cytochrome P450 enzymes.¹ This is a meaningful practical distinction. Because it largely sidesteps the P450 system, metopimazine has a lower likelihood of interacting with other drugs that compete for those enzymes. Cancer patients, who are often taking multiple medications simultaneously, stand to benefit from that reduced interaction potential. The same applies to gastroparesis patients, who frequently take other medications for diabetes, pain, or mood disorders.

The amidase pathway rapidly converts metopimazine into metopimazine acid, which then circulates in the blood at much higher concentrations than the parent drug. Because metopimazine acid retains the ability to block D2 receptors but crosses the blood-brain barrier even less effectively, the metabolic pathway essentially transforms the drug into a version of itself that is both active and safer. It is an unusually convenient piece of pharmacology, and researchers have pointed to it as a key reason the drug’s clinical side-effect profile has remained favorable over decades of use.⁸

Why Metopimazine Stayed Regional for So Long

It is reasonable to wonder why a drug with a favorable side-effect profile, decades of clinical use, and a mechanism that complements existing treatments never made it to the world’s largest pharmaceutical markets. The answer is mostly commercial and regulatory rather than scientific. Metopimazine was developed and marketed by a French pharmaceutical company at a time when the drug approval process was much more nationally focused. A drug could succeed in France without ever seeking regulatory approval in the United States or the United Kingdom. By the time global drug development became standard practice, metopimazine was a mature, off-patent product without the commercial incentive for an expensive international registration campaign.

The emergence of 5-HT3 antagonists like ondansetron in the early 1990s also shifted the landscape. Ondansetron became the dominant antiemetic for chemotherapy worldwide, and the momentum behind new entrants in that space diminished. Metopimazine’s niche as a D2 blocker with unusually good tolerability was clinically relevant but commercially modest. It took the recognition that gastroparesis represents a large underserved market to create the financial incentive for a company to invest in bringing metopimazine through the FDA’s approval pathway under a new formulation. Whether that investment pays off remains to be seen, but it has at least put the drug on the radar for clinicians and patients who had never heard of it.